Podcasts about maintain

Dr. Allen Lycka was a leading cosmetic dermatologist in the prime of his life when he was diagnosed with ALS and given six months to live. After fighting the diagnosis, he is here today as a result of his courage, determination and self advocacy.  Turns out Dr. Lycka had lyme disease not ALS.  After being treated for chronic lyme Dr. Lycka became a transformational speaker, thought leader, coach, mentor and author who used his experience to co-author the book The Secrets of Living A Fantastic Life with Harriet Tinka.  He has been a guest on dozens of television, radio shows and podcasts, as well as featured in numerous newspaper articles, blogs, and magazines.  In this episode of The Health Fix Podcast, Dr. Jannine Krause interviews Dr. Lycka on his 13 pearls to live a fantastic life.  What You'll Learn in This Episode: Always look for second opinions & outside the box for answers Keep asking questions about your health Maintain hope & keep searching for answers Mindset everything when it comes to chronic illness Don't settle for black & white answers, explore the gray Resources From the Show: How to Live a Fantastic Life - Dr. Lycka's Podcast Coaching with Dr. Allen Lycka   Enjoy The Show? Never Miss An Episode Subscribe, Rate and Review the show in iTunes Subscribe via Stitcher or RSS feed Send us feedback via Email Leave a comment below

Today Alex & Richarrd invite Dennis the biggest Drake hater to the Maintain podcast to discuss the Detroit Pistons and give a review on Drake's "Honestly, Nevermind". Make sure to drop a like on the podcast and subscribe for more podcasts like this one!00:00 Intro00:11 Nba Draft00:54 Dennis & Woo try to convince Richarrd about Cade Cunningham1:29 Detroit Pistons are back!5:22 Who's the biggest NBA draft bust ever?6:51 Praying for Lil Tjay10:13 Best NBA 2k Ever?11:30 Woo & Dennis's My park stories14:02 Top 3 characters of all time17:42 LIVE REACTION to the Pistons trading for Jalen Duren 18:36 Dennis FaceTimes his friend for an explanation of the trade21:22 Drake album reaction/review 26:11 Drake Vs. Kanye28:02 When did Dennis decide he was done with Drake's music28:35 Dennis is a Drake hater 29:10 Drake's not trying as hard anymore32:00 Dennis says “Jesus Is King” is better than “Honestly, Nevermind”36:38 Is it okay to ask your partner how many people they've slept with?42:05 Dennis Vs Richarrd 1v1 basketball???YOUTUBE: https://youtu.be/PlXcmijOHHwASK US QUESTIONS FOR OUR NEXT EPISODE: https://www.surveymonkey.com/r/96H5H59https://www.surveymonkey.com/r/96H5H59FOLLOW US ON INSTAGRAM:https://www.instagram.com/thatstarwoohttps://www.instagram.com/charrd__https://www.instagram.com/maintainnetworkhttps://www.instagram.com/dennis_oskarekFOLLOW US ON TIK TOK: https://www.tiktok.com/@maintainnetwork?is_from_webapp=1&sender_device=pc

Tara Rynders joins Ethics Talk to discuss her article: “How the Arts Help Us Hold Grief and Maintain Collective Care” Recorded April 20, 2022  Read the full article here.

The Family Education Rights and Privacy Act seems pretty straightforward: Maintain confidentiality and produce records to parents or adult students. But what happens when a record, like a video, includes information about more than just one student? What is the procedure when the requesting party is an attorney or a police officer? What about parents who want to observe their children's in-person or virtual classes? Join Christina, Lisa, and Miriam as we discuss your top FERPA questions and consider how school districts across the country are addressing challenging situations that may implicate student privacy rights. Previous seasons of this podcast, including Season One, are available at https://www.walterhav.com/podcasts-index/We practice law, including special education law, at Walter Haverfield in Cleveland, Ohio, and we welcome your suggestions and comments. Please check us out at:https://www.walterhav.com/professional/christina-henagen-peer/https://www.walterhav.com/professional/lisa-h-woloszynek/https://www.walterhav.com/professional/miriam-m-pearlmutter/

Solidarity 640, 29 June 2022, articles: Get the Tories out! Labour: demand a debate on Brexit Back Ukraine's call for arms supplies Political ripples from the war Steve Sweeney, Ukraine and Russia The CPB on 18 June Trade unionist's pre-trial arrest extended USA rolls back women's rights A system of minority rule The North York Moors and extinction “Kick the Tories out” and socialist politics Stop the Rwanda scheme, oppose new Tory Bill Action on Covid-19 Police break up Istanbul Pride A public service railway! Make Labour back the pickets What should our pay demand be? Maintain momentum after magnificent week! Connolly on partition (2) NHS: organise now to win on pay How to make Unison “strike-ready” School workers' pay: a long road yet Diary of a trackworker: Back to the flying pickets? Momentum calls its election Building for September (John Moloney's column) Preparing to renew courier pay fight UCU Congress dodges Ukraine Wakefield does not vindicate Starmer Make wages spiral! More online: https://workersliberty.org/publications/solidarity/solidarity-640-29-june-2022

Before this episode: Relationships feel uncertain. Uou don't know what to say. Lots of awkward silence. After this episode: Confidence in your relationships. Endless conversations. The sound of laughter. Give this episode a try! Your relationships are guaranteed to get better. Say It With Me - Appreciate Learn 2 rules about showing appreciation that your leader will appreciate. These rules position you in places of authority and leadership. 2 minutes into this episode and you'll hear a story that changes your perspective. Prophet, this is the best way to promotion in your church. Now, join your spiritual parents, Craig and Colette Toach. Go through your prophetic process quicker. Join the Prophetic Mentorship Program mypropheticmentor.com Scriptures That Season Your Words With Salt Matthew 10:41 (NKJV):He who receives a prophet in the name of a prophet shall receive a prophet's reward. And he who receives a righteous man in the name of a righteous man shall receive a righteous man's reward. Related Episodes How Tone Has the Power to Deliver Your Prophetic Word in Style (Ep. 243) Join Our Community! https://www.apostolic-network.com Sponsor the NextGen Prophets Podcast Take this message further. Be responsible for raising the next generation of prophets. Get Your Free E-book and Course Here https://www.nextgenprophets.org/ Watch Our Free Prophetic Teachings on Youtube https://www.youtube.com/ToachMinistries Give us a Call! Phone: 760 466 7257 Get Connected With Apostles Craig and Colette Toach Submit Your Question to the Apostles: ToachMinistries.com Follow the NextGen Prophets Facebook: NextGen Prophets Follow the NextGen Prophets Instagram: NextGen Prophets Instagram

Join me this week on "Maintain the Flame" as I interview long-term missionary to The Philippines, Eric Miller. Hear of God's faithfulness and power as Eric shares about his calling, vision, and the things that the Lord has done over the many years that he and his family have been on the mission field. Be prepared to be greatly encouraged as you listen!

Losing weight AND maintaining it can be easier said than done. Losing weight isn't always the hardest part, as oftentimes, it's keeping it OFF and maintaining that progress that deems itself as being the more difficult task at hand. In this episode, Coach Lexie and Matt discuss this topic. 

THE HEAT, HUMIDITY, AND INCREASE IN OUTDOOR ACTIVITY IN THE SUMMER CAN MAKE US FEEL LESS THAN FRESH...EVERYWHERE! Dr. Susan Oakley gives us tips on maintaining good summer hygiene down there. Summer is a tricky season for maintaining feminine health. Temperatures rise, swimsuits are worn in lieu of breathable underwear, and sunscreen and sweat live on the skin for long periods of time. It's no wonder that vaginal irritation, yeast infections, and more become the common scourge of summer. Luckily, there are practical steps you can take to keep your vagina healthy. Maintain vaginal health with topical hormones and oral supplements as directed by your physician. Dr. Oakley loves and recommends Utiva to her patients and she takes it daily. Check it out: https://www.utivahealth.com/ - Her favorite is the Utiva Cranberry PACs: it's a simple, small, once-a-day pill taken for daily support of the urinary tract to prevent ongoing UTIs. PACs are also the antioxidant of the cranberry and provide other gut health benefits. Love it!! Thank you for listening. Please send in your comments, questions and suggestions for future topics at TheLadyBodPod@gmail.com. For more details on the LBP: https://theladybodpod.com/

Balance is crucial to our overall well-being. But it can be challenged at any age, and we start to lose our balance in our 50s. The good news is that simple exercise can help maintain and even restore balance. Lisa Hoffart, a physiotherapist with Canadian Sport Institute Calgary and Group 23 Sports Medicine helps answer: Why is it important to maintain my sense of balance as I age?

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: Cardio can ACTUALLY help you build muscle. (4:20) Kids do silly things when they are young. (11:47) Justin had a great Father's Day. (22:04) Euphoria is too much for Sal. (24:52) The HUGE difference between targeted vs. broad supplementation and what Equi.Life brings to the table. (27:54) An update on the live listener call in with a swollen arm. (30:56) Ned's full-spectrum hemp oil is LEGIT! (34:40) Not so trendy. (38:44) World Swimming Org bans trans women athletes that are past puberty age. (40:12) #ListenerLive question #1 - Is 3.5 hours of activity too much per day? Should I cut movement and calories? (46:37) #ListenerLive question #2 – What is your advice for someone who wants to maintain their fitness while on an extended travel leave with limited equipment? (58:01)  #ListenerLive question #3 - After completing MAPS Performance I had a significant strength increase from MAPS Anabolic phase 1, to MAPS Aesthetic phase 1, and don't recall this the last time I went through the mesocycle. How/why is that possible? (1:03:28) #ListenerLive question #4 - Any insight on a good approach on how to wear my rucksack to avoid fatiguing my core? (1:10:18) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Equi.life is offering all Mind Pump listeners an at home Minerals & Metals At-Home Lab Test for 50% off! Visit NED for an exclusive offer for Mind Pump listeners! Special Launch: MAPS Cardio, plus two special e-books for $77! (Ends 7/3) **Promo code CARDIOSPECIAL at checkout** June Promotion: Shredded Summer Bundle or MAPS HIIT 50% off! **Promo code JUNE50 at checkout** Mind Pump #1845: How To Do Cardio & Not Lose Muscle Monterey Beach Resort | The Sanctuary Beach Resort Euphoria | Official Website for the HBO Series | HBO.com Watch God's Favorite Idiot | Netflix Official Site Watch Hustle | Netflix Official Site MP Holistic Health FINA votes to restrict transgender women from swimming events Visit MASSZYMES by biOptimizers for an exclusive offer for Mind Pump listeners! Mind Pump #1142: Nine Signs You Are Overtraining No BS 6-Pack Abs | MAPS Fitness Products MAPS Fitness Anabolic MAPS Fitness Anywhere MAPS Suspension Training MAPS Symmetry MAPS Fitness Performance Visit Drink LMNT for an exclusive offer for Mind Pump listeners! Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Dr. Stephen Cabral (@stephencabral)  Instagram

In this episode, Mike and Randy explain how to care for your outdoor fireplace, including what kind of maintenance is required, why it's important, and when to hire a pro.

Become a PREMIUM podcast subscriber to support this show and you will get Access to the first 200+ episodes (no longer on other platforms) Access to the entire 500+ episode archive Early access to regular episodes (before they're released publicly) Access to additional bonus material releases Exclusive, subscriber-only audio replies to “Ask Me Anything” questions In episode 542 of The Half Size Me™ Show, Heather chats with Heather about her struggles maintaining a 100-pound weight loss, plus they discuss how to deal with obsessive food thoughts how to plan for snacks how to manage exercise and more! Do you want to get support and connection at a price you can afford? Then check out the Half Size Me Community here: https://halfsizeme.com/join About Half Size Me The Half Size Me™ Show is a weekly podcast. It will inspire and motivate you no matter where you are in your weight loss journey. Whether you're just getting started losing weight or having worked on your health and wellness for years, this show is for you! The Half Size Me Show is hosted by Heather Robertson, who lost 170 pounds over a period of about 5 years. Heather did it by learning new eating habits, getting regular exercise, and changing her mindset. On her popular weekly podcast, The Half Size Me Show, Heather shares her own lessons and struggles with you, and she shows you how to handle the real challenge of any weight loss journey... weight maintenance. Be sure to subscribe to The Half Size Me Show and join Heather every week as she shares information, inspiration, coaching, and conversations with REAL people who've learned weight loss isn't only about losing pounds, it's about finding yourself. Disclaimer: Heather is not a doctor, nurse, or certified health professional. What worked for her or her guests may not work for you. Please talk with your doctor, dietician, or other certified health professionals when seeking advice about your own weight loss or weight maintenance plan. All information included in The Half Size Me™ Podcast and on HalfSizeMe.com is for informational and inspirational purposes only. For additional disclaimer information, please visit HalfSizeMe.com. To contact Heather about the show, please click here to use the contact form.

Andy Paul is an author, a podcaster, a speaker, and a consultant. He is ranked #8 on LinkedIn's list of Top 50 Global Sales Experts. He is the owner and the host of the podcast "Sales Enablement with Andy Paul,” the show already has over a thousand episodes and continues to inspire thousands of sales professionals every week. Andy has also written two award-winning sales books, "Zero-Time Selling" and "Amp Up Your Sales". He recently published the book “Sell Without Selling Out.” Discover why Andy decided to remain in sales and what motivates him.   Full show: https://wethesalesengineers.com/show219

The Gospel and a Sinful Culture Deuteronomy 25:5-6 5 If brothers dwell together, and one of them dies and has no son, the wife of the dead man shall not be married outside the family to a stranger. Her husband's brother shall go in to her and take her as his wife and perform the duty of a husband's brother to her. 6 And the first son whom she bears shall succeed to the name of his dead brother, that his name may not be blotted out of Israel. The Gospel and a Sinful Culture 1. The Bible grounds identity and sexuality in God's creation design. 27 So God created man in his own image, in the image of God he created him; male and female he created them. 28 And God blessed them. And God said to them, “Be fruitful and multiply and fill the earth and subdue it, and have dominion over the fish of the sea and over the birds of the heavens and over every living thing that moves on the earth.” ---Genesis 1:27-28 (ESV) 24 Therefore a man shall leave his father and his mother and hold fast to his wife, and they shall become one flesh. ---Genesis 2:24 (ESV) 2. The Bible doesn't glorify sexual sin. 3. The Bible declares the only appropriate place for a sexual relationship is between a husband and wife. 18 Flee from sexual immorality. Every other sin a person commits is outside the body, but the sexually immoral person sins against his own body. 19 Or do you not know that your body is a temple of the Holy Spirit within you, whom you have from God? You are not your own, 20 for you were bought with a price. So glorify God in your body. ---1 Corinthians 6:18-20 (ESV) 4. Even though God gives standards of holiness, God's people don't always live up to those standards. 5. God doesn't cancel us in our sinfulness. 6. If God doesn't cancel us in our sinfulness, we shouldn't be so quick to cancel others in their sinfulness. 7. Remember, we lose the culture war before Christ wins the culture war at His return. What should we as Christians do? 1. Maintain and exalt a biblical sexual ethic. 2. Strive to nurture relationships that already exist. 3. Respect your own conscience. 4. Be generous with prayerful grace. 5. Prayerfully seek opportunities to speak and display the gospel's work in your own life.

Welcome to Sunday's Solo Episode #455.   During this episode, I talk about the 5 Pillars to Running a Successful Business - Finance, Team Marketing, Logistics, Organisation Skill, and Sales. Here are some highlights: To be able to grow a successful team, you need to employ the right people for the right roles. The biggest challenge that 99% of people that I've interviewed over the last five years say that those are the two hardest things to do, recruit the right people, keep the right people. Cash is oxygen for your business. Maintain a consistent pipeline of leads and prospects and turn these leads to customers.   Learn more about the contents discussed in this episode: Connect with me via LinkedIn, Twitter, Facebook, Instagram, Clubhouse

Welcome to the trailer for Episode #455.   In this Sunday Solo episode, I will be talking about the 5 Pillars to Running a Successful Business - Finance, Team Marketing, Logistics, Organisation Skill, and Sales. Here are some highlights: To be able to grow a successful team, you need to employ the right people for the right roles. The biggest challenge that 99% of people that I've interviewed over the last five years say that those are the two hardest things to do, recruit the right people, keep the right people. Cash is oxygen for your business. Maintain a consistent pipeline of leads and prospects and turn these leads to customers.   Join us on Wednesday for the full episode.

 Learn how to really attract your crush by becoming magnetic to women. In today's video you'll learn how to impress women with the things they always notice on a guy.  #Joyanima #Dating #Crush 0:00 Intro 1:12 How to be magnetic to women 1:19 Smell good 2:16 Your dress sense 3:39 Have humour 4:23 Listen with intent 5:20 Maintain eye contact 5:40 Be confident

Blade depth on the drive | Faster Masters Rowing Radio Support this show with a donation https://fastermastersrowing.com/podcast Timestamps 02:30 Keep the top edge consistent level and covered at this height through the drive. Important for an effective drive. It affects the length of time the oar is in the water. 04:00 common errors with blade depth Going too deep The blade has floatation and will sit in the water at the correct height if you just leave it with no pressure. Add pressure to the blade does bury it a little more. Lifting the hands too high causes deep blades. Use the reference point for the handle “aim for where your knees were” Norm Graaf advice. Opening up the body too early on the drive sequence. If the body lifts away from the knees this causes the blades to go too deep “rowing up over the barrel”. 07:00 The blade is not fully square when it goes into the water. This causes it to dive deep. Is there enough height above the water to square on the recovery? A solution is to relax the handle. If you hold too tightly the water isn't able to fix the blade depth and square placement. 09:30 Drills and skills to build blade power Blade depth drills Row in circles - leave one blade flat on the water with the handle next to your body. Row with the opposite hand. Watch your blade as you row - make corrections to the depth. Check the waterline on the oar shaft - it should stay consistent until the oar comes out of the water. 13:45 Backing down drill Keep the blades in the same position as you row (don't counter-feather). Build your confidence increasing the stroke length from arms only to full slide backing. You can see your blades as you back. Practice the correct recovery sequence - arms / body / legs flow up the slide as your hands separate. Practice in sweep and sculling boats. 16:30 Half blade depth drill Row with your oars half way out of the water. Requires more control over the oar - finesse. You can't row hard but allows you to practice the handle control. Practice full blade depth as well. 20:00 Bungee rowing drill - put the elastic bungee to the stern of your foot stretchers. This slows down the boat on the recovery and gives you resistance feedback. Try rowing one stroke with power and one light pressure easy alternating. Goal is to apply pressure to the handle keeping the blade at the correct depth. 4 sets of 8-10 strokes focusing on higher power. 21:45 Vary pressure through the stroke drill. Change from quarter to half pressure (50%) at the release. Row 20 strokes with this focus. Then go from 50% up to 75% pressure at the release. Maintain handles horizontal and drive length through the water. Lastly try 75% up to 100% full pressure. 23:30 The silent pyramid exercise This helps build up to full pressure strokes; it also helps concentration. Start with 1 stroke with power and 1 stroke easy light pressure; then 2 on and 2 off; 3 on / off; Up to 10 strokes with power and 10 strokes off easy - then work your way back down the pyramid, 9 - 8 - 7 down to 1 stroke. 26:00 Managing training with long Covid The effects take a long time to recover after illness. A useful measurement is heart rate variability. Morning resting heart rate gives you a norm. If you are fatigued from training this will change - elevate. Rule of thumb 5 beats above normal you should take it easy that day or do a light training to keep your heart rate low. 28:30 Heart rate variability - measures the amount of time between heart beats. This reacts to how much fatigue you have and indicates if your body is in a relaxed or stressed state. It indicates whether your sympathetic nervous system is over-active (fight or flight). In a relaxed state your parasympathetic nervous system is activated. Measure using an app HRV4Training it measures heart rate and asks questions about your lifestyle - sleep, training, injury. The factor is personal to you and indicates what's normal for you.

As a single person, have you feared losing yourself in marriage? Have those thoughts made you have cold feet in deciding whether you want to get married? I have those thoughts too! and on this episode are commentaries from married people on how this fear may be valid but shouldn't be a hindrance. These women share experiences from being married for years, and how they maintain their individuality and not lose themselves. Send me an email: ritachukwuike@gmail.com DM on Instagram @thegirlunplugged

Dr. James Goodwin, a professor and director at the Brain Health Network, joins Tristan to discuss the research in his new book, Supercharge Your Brain: How to Maintain a Healthy Brain Throughout Your Life. They discuss how diet, exercise, and other mindful behaviors can sharpen your cognition and keep your brain in optimal health throughout your life. See omnystudio.com/listener for privacy information.

Dr. James Goodwin, a professor and director at the Brain Health Network, joins Tristan to discuss the research in his new book, Supercharge Your Brain: How to Maintain a Healthy Brain Throughout Your Life. They discuss how diet, exercise, and other mindful behaviors can sharpen your cognition and keep your brain in optimal health throughout your life. See omnystudio.com/listener for privacy information.

Dr. James Goodwin, a professor and director at the Brain Health Network, joins Tristan to discuss the research in his new book, Supercharge Your Brain: How to Maintain a Healthy Brain Throughout Your Life. They discuss how diet, exercise, and other mindful behaviors can sharpen your cognition and keep your brain in optimal health throughout your life. See omnystudio.com/listener for privacy information.

Dr. James DiNicolantonio shares amazing tips about how salt, hydration and sauna strategies can help improve strength and exercise performance.  Support your Exercise Performance with the new Electrolyte Stix by MYOXCIENCE Nutrition: Save with code podcast at checkout Get Jame's New book Win: Time Stamps 03:15 Maintain your muscle and cardiovascular health through exercise. Reduce the risk of sarcopenia with resistance training, 30 – 60 min 3 – 4 times per week. Running at 60 – 70% of your max heartrate boosts your endurance. HIIT or super maximal interval training 2 – 3 times per week helps your cardiovascular system. 07:10 Preloading with salt and fluids is 10 to 20 times better than other supplements. Dosing salt correctly, allows you to exercise up to 20 minutes longer. Beta alanine allow you to vigorously exercise 1 to 2 minutes longer. 07:40 The main benefit from preloading with salt and fluids is from the boost in blood volume prior to vigorous exercise. You have an 8 to 10% drop in blood volume within 5 minutes of vigorous exercise.  The biggest adaptation during vigorous endurance exercise is the attempt to increase baseline blood volume. 08:54 Elite athletes have a 40% increase in blood volume over typical males and females. High doses of salt and fluids should be reserved for just prior to competition. 10:32 Dehydration acclimation, inducing mild amounts of dehydration multiple times, can help build blood volume. 12:05 Before a typical workout, you can ingest 1,000 mg of sodium and 10 to 16 ounces of fluid. High levels used for competition would be 3,000 to 4,300 mg of sodium and about 26 ounces to 33.8 ounces of fluid. This matches to saltiness of your blood. 13:40 Increased blood volume increases cardiac output, decreases oxygen demand on the heart and gives you a larger volume to dissipate heat. We lose blood volume to sweat. You can better pull waste from your cells and better deliver nutrients. 15:30 Sauna therapy is similar in metabolic adaptations to dehydration therapy. When you become heat activated, your baseline core body temperature becomes lower. You have a larger pool to soak up heat. You can train and perform longer before the enzymes that produce ATP start shutting down. 16:05 When you are heat activated, your sweat becomes more dilute. You lose fewer electrolytes. The diluted sweat evaporates faster, so your cool faster. 16:34 To become heat activated, you need to do a sauna session every day for 2 weeks or so, raising your core body temperature to 101.3 and maintain it for 20 to 30 minutes. You can go as few as 4 days per week, but it will take you longer to achieve being heat activated. The benefits of doing this will last as long as 2 weeks, as long as you maintain a good exercise program. 18:57 Endurance exercisers with large blood volumes typically have good blood pressure. As long as your arteries vasodilate well, and you do not have increased vasoconstriction with increased blood volume, you should not see an increase in blood pressure. 20:07 Body temperature is highly influenced by circadian biology. Post exercise sauna for 13 sessions, improves performance by about 10%. 23:28 Postpone your cold plunge for 2 to 4 hours after exercise, if your goal is hypertrophy. Sooner than that inhibits some of your muscle size and strength gains from exercise. Elite athletes plunge directly after exercise to limit inflammation and accelerate recovery. 26:55 Exercise timing is individual and depends upon whether you are a morning person or a night owl. About 8 hours after you wake up is typically when you perform at your best. Your cognition is shot for a few hours after vigorous exercise. Exercise close to bedtime impacts your ability to go to sleep. 29:20 Avoid caffeine at least 6 hours before bedtime. 31:48 If you are a vegetarian, you are not getting many nutrients found in red meat. Carnitine is important for fat oxidation for fuel. Carnosine is an advanced glycation end product inhibitor and buffers acid produced during exercise. Beta alanine boosts carnosine levels. Taurine is an amino acid that helps with blood pressure, blood flow, antioxidant status in the central nervous system.  33:45 Red meat is more nutrient dense than chicken. Pork is 10 times higher in thiamine (vitamin B1). Consume liver (for vitamin A and copper) and heart (for coQ10) on a fairly consistent basis.  Many of us are deficient in vitamin A and copper and anemia is driven by this. 35:10 Creatine improves cognition. 50% of methylation is for the creation of creatine in your body. Supplementing frees up that effort for you body. 36:35 Supplementing 3 to 5 grams of creatine per day brings most benefits. Eating red meat may not get you to that level. 37:20 The more hydrated your muscle is, the better blood flow, oxygen delivery and pump you get. Your muscle is about 75% water. Creatine enhances cell hydration. 38:40 Supplementing with creatine at doses of 5 grams per day is completely safe. 39:40 To induce hypertrophy, the key is to go near or to failure. Heavy weight is not necessary. Inositol helps to improve insulin sensitivity, thus preserving muscle mass. 41:51 For prolonged vigorous explosive activity, preloading with carbs improves performance. It helps you to tap your muscle glycogen reserves. There are benefits to training fasted. Metabolic flexibility is when you can burn either fats or carbs. 42:50 It is taxing to force your body to make glucose, rather than ingesting exogenous glucose. 45:00 Longevity populations are generally smaller and have less muscle mass than Americans, so they can get away with lower protein intake. Our needs are higher. 46:42 Exercise improves insulin sensitivity. Insulin resistance chronically elevates mTOR. 48:40 Elevated LDL (outside of genetic influences) is not a risk factor for increasing heart disease, in the face of good insulin sensitivity, low triglycerides, and good HDL. 49:30 Oxidized LDL is a contributor to heart disease. The amount of linoleic acid in LDL influences oxidation. Eating heart for ubiquinol and eating high quality meat for carotenoids, helps to protect LDL from oxidation. Increasing olive oil consumption increases monounsaturated fats in LDL, decreasing susceptibility to oxidation. 51:30 When you replace animal fats with vegetable oils, there is an increase in all-cause mortality. LPa is a functional marker of oxidation, with elevated LDL. 55:05 Salt intake recommendations are based upon expert opinion, not clinical evidence, or meta-analysis. Lowering salt intake barely lowers blood pressure. Some may have an increase in blood pressure with the decrease of salt intake. Decreases in blood pressure from reducing salt is from depleting blood volume. Stress hormones increase. 56:00 When you go below 3000 mg of sodium, all the stress hormones increase. Insulin resistance increases as well. 3000 to 5000 mg of sodium is associated with the least amount of rise in stress hormones and the lowest amount of risk of cardiovascular disease.

In this episode, Greg Bell shares how you can reframe a challenging situation so you can learn how to deal with it successfully.    Order the Water the Bamboo Book at https://amzn.to/3mPxcZu Order the What's Going Well? Book at https://amzn.to/3rBePLy  Learn more about Greg Bell More than just a motivational speaker, Greg Bell is a Portland, Oregon-based thought leader, business consultant, and leadership coach. His popular books, What's Going Well? and Water The Bamboo: Unleashing The Potential Of Teams And Individuals, have inspired an array of organizations, from Fortune 500 companies like Nike, Disney, and Comcast, to the Portland Trail Blazers and Division I NCAA athletic teams like the Oregon Ducks Football and the Gonzaga Bulldogs Basketball.  Visit Greg's website. Connect with Greg LinkedIn | Facebook | Instagram | Twitter

Episode Summary: Bunny Yekzaman and I talk about how to maintain hope while waiting for the salvation of a loved one. My guest today was a Christian when she married a Muslim. She was in love and thought it was her job to save him. She'll share what transpired and what she learned through it on today's episode. Quotables from the episode: There are two ways of praying: in faith or in doubt. When praying for our lost loved ones to be saved, we must ask God in faith without doubt. If we pray His will, we have the confidence that He will answer those prayers. We can't prove God to someone—He proves Himself. My love for God kept me in my marriage…not my love for my husband. God took my mess and used it to create my message. Prove God's love to your loved ones by loving them regardless of how they respond to you. When I think of and pray for my lost loved ones, I have to first remember I was once lost. Scripture References: 1 John 5: 14-15 “This is the confidence we have in Him, that, is we ask anything according to His will, He hears us, and if we know that He hears us in whatever we ask, we know that we have the request we have asked of Him.” 2 Peter 3:9 “The Lord is not slow about His promise, as some count slowness, but is patient toward you, not wishing for any to perish but for all to come to repentance.” Philippians chapter 4:6-7 NASB "Be anxious for nothing, but in everything by prayer and supplication with thanksgiving let your requests be made known to God. And the peace of God, which surpasses all comprehension, will guard your hearts and your minds in Christ Jesus." James 1: 6-7, 19 NASB "But he must ask in faith without any doubting, for the one who doubts is like the surf of the sea, driven and tossed by the wind. For that man ought not to expect that he will receive anything from the Lord, 8being a double-minded man, unstable in all his ways. And my God shall supply all your needs according to His riches in glory in Christ Jesus." 1 Corinthians 7:12-16 "But to the rest I say, not the Lord, that if any brother has a wife who is an unbeliever, and she consents to live with him, he must not divorce her. And a woman who has an unbelieving husband, and he consents to live with her, she must not send her husband away. For the unbelieving husband is sanctified through his wife, and the unbelieving wife is sanctified through her believing husband; for otherwise your children are unclean, but now they are holy. Yet if the unbelieving one leaves, let him leave; the brother or the sister is not under bondage in such cases, but God has called us to peace. For how do you know, O wife, whether you will save your husband? Or how do you know, O husband, whether you will save your wife?" Recommended Resources:  The Power of the Praying Wife By Stormie Omartian Beloved Unbeliever by Jo Berry 10 Minute Turnaround Courses: 10 Minutes a Day Unlocks the Secrets to Change Your Life  Today is Going to be a Good Day: 90 Promises to Start Your Day Off Right by Dr. Michelle Bengtson Trusting God Through Cancer 1 Trusting God Through Cancer 2 Revive & Thrive Women's Conference YouVersion Devotional, Today is Going to be a Good Day version 1 YouVersion Devotional, Today is Going to be a Good Day version 2 Free Download: How To Fight Fearful/Anxious Thoughts and Win Breaking Anxiety's Grip: How to Reclaim the Peace God Promises by Dr. Michelle Bengtson Breaking Anxiety's Grip Free Study Guide  Free 7-Day YouVersion Bible Reading Plan for Breaking Anxiety's Grip Hope Prevails: Insights from a Doctor's Personal Journey Through Depression by Dr. Michelle Bengtson, winner of the Christian Literary Award Reader's Choice Award Hope Prevails Bible Study by Dr. Michelle Bengtson, winner of the Christian Literary Award Reader's Choice Award How To Help a Depressed Loved One free eBook Social Media Links for Host and Guest: Connect with Bunny Yekzaman Website / Facebook / Instagram For more hope, stay connected with Dr. Bengtson at: Order Book Breaking Anxiety's Grip / Order Book Hope Prevails  /  Website  /  Blog  /  Facebook / Twitter (@DrMBengtson)  /  LinkedIn  /  Instagram / Pinterest / YouTube Guest: Bunny Yekzaman is a child of the King, a wife of 42 years, mother of 4 & grandmother of 8.  She is a disaster relief chaplain, and works as an Enrichment specialist for a nursing home. Her passion is sharing God's love & truth with a faith in His faithfulness to His promises. She lives with hope for her lost family and friends and finds it her calling to pray in faith for them. Hosted By: Dr. Michelle Bengtson Audio Technical Support: Bryce Bengtson

Join me this week on "Maintain the Flame" as I interview long-term missionary to The Philippines, Eric Miller. Hear of God's faithfulness and power as Eric shares about his calling, vision, and the things that the Lord has done over the many years that he and his family have been on the mission field. Be prepared to be greatly encouraged as you listen!

In today's Audio Episode #789 of the "Digital Pratik Reloaded, "Digital Pratik talks about how can one grows their social media channel in 2022, even after the evolution of Web 3.0" Connect with me on my other social accounts for more contextual content, offers & updates: My NFT: https://opensea.io/collection/jorrparivar Twitter: https://twitter.com/digitalpratik YouTube: https://digitalpratik.com/youtube Gujju YouTube: https://bit.ly/gujjudpyt LinkedIn: https://linkedin.com/in/digitalpratik Facebook: https://facebook.com/digitalpratik

Today's Success Stories podcast is all about how you find new information and put it to use in your shop.  Terry Keeven with St. Louis Print Company has been refining his business since 2007 with new ideas.  We'll learn where these ideas come from, how he is implementing them, and what it takes to get continuous improvement changes working in a business.Get ready to hear some impactful information that could make a tremendous impact on your shop!So Terry, welcome to the Success Stories podcast!

Summer is in full swing! That's why today I'm sharing 3 simple things I do every single day to help myself stay productive and keep moving the needle forward in my business during this fun, crazy, and often busy season.  GET CONNECTED: Join the Wildly Aligned Marketing Facebook group. Book your free Marketing Clarity Call to identify why you're not consistently finding and attracting the right clients.

Dr. Allison Zibelli, of the Sidney Kimmel Cancer Center – Jefferson Health, and Dr. Hope Rugo, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discuss the practice-changing DESTINY-Breast04 trial as well as novel therapies in metastatic HR+/HER2- breast cancer from the TROPiCS-02 and MAINTAIN studies, all of which were featured at the 2022 ASCO Annual Meeting.   TRANSCRIPT Dr. Allison Zibelli: Hello. I'm Dr. Allison Zibelli, your host for the ASCO Daily News Podcast today. I'm a vice-chair and breast medical oncologist at the Sidney Kimmel Cancer Center, Jefferson Health in Philadelphia. My guest today is Dr. Hope Rugo, a professor of medicine and the director of Breast Oncology and Clinical Trials Education at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. We'll be discussing key advances in breast cancer that were featured at the 2022 ASCO Annual Meeting. Our full disclosures are available in the show notes, and disclosures of all guests on the podcasts can be found on our transcripts at asco.org/podcasts. Hope, it's great to talk to you today. Dr. Hope Rugo: Nice to talk to you, too. Dr. Allison Zibelli: Let's begin with perhaps the most exciting abstract at ASCO this year, which was the DESTINY-Breast04 study, that's LBA3, a randomized phase 3 study of trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-low, unresectable and/or metastatic breast cancer. What are your thoughts about this study? Dr. Hope Rugo: Well, of course, this is a hugely practice-changing study as was noted in the second-to-last slide by the discussant [Dr.] Pat LoRusso. So, antibody-drug conjugates are really the next step in delivering chemotherapy to cancer cells. The antibody-drug conjugates allow targeted delivery of a toxin to the cancer cell. I think we didn't understand how important this was going to be. These second, sort of, verging on third-generation antibody-drug conjugates use an antibody approach and to then have a new generation of linkers, which allow the drug to be released locally, but to then have drugs which pack a big bang for the buck. So, the way antibody-drug conjugates are constructed, you need to have a drug that actually can't be given as a naked drug because it's too toxic because you're giving just very small amounts of this drug that are delivered directly to the cancer cell. And the other really critical part of this is that the drug-to-antibody ratio of at least the successful and new antibody-drug conjugates (ADC) is quite high in the 7.5 to 8 toxins per antibody. Now, what that's resulted in is really interesting, is that there's a bystander effect. So, the toxin itself can leak out of the cancer cell that it's targeted and kill neighboring cells, but also because of the construct of these antibody-drug conjugates, what's likely happening is even if the cancer cell's a very low expression of the target, really low, you're able to actually get that ADC into the cancer cell to kill the cancer cell. So that may be a big part of the so-called bystander effect. So trastuzumab deruxtecan is biosimilar trastuzumab linked to a topoisomerase inhibitor deruxtecan, and what happened here was that of course, we saw remarkable data in HER2+ disease, unbelievable p-values in DESTINY-Breast03 compared to T-DM1, a first-generation ADC. But in DESTINY-Breast04, we targeted a population of patients largely with hormone receptor-positive disease who had a little expression of HER2, 1 plus or 2 plus by immunohistochemistry and no gene amplification. And this trial, which randomly assigned patients 2:1 and included just 58 patients with triple-negative disease. So in this trial, 480 had hormone receptor-positive breast cancer, a median of 1 line of prior chemotherapy. They were only allowed up to 2. They were refractory to endocrine therapy, a median of 3 lines of endocrine therapy. In the overall patients and in the hormone receptor-positive patients, there was actually a doubling in progression-free survival (PFS). It started very early, and it continued throughout, and at every landmark analysis, T-DXd was better than the treatment of physician choice that patients were randomly assigned to. It's also important when you're thinking about trials like this to think about what the treatment of physician choice was, and it was all chemotherapy regimens we would use. Paclitaxel, nab-paclitaxel, capecitabine, eribulin, or gemcitabine. And, so, I think that that doesn't bring up any questions. When they looked at the hormone receptor-positive group, they saw, if anything, even a bigger benefit overall. Now, the other endpoint of this trial was overall survival, and at this first analysis, they saw an improvement in overall survival that was quite dramatic. The absolute difference was 6.4 months, which is pretty amazing for an overall survival difference. And then they looked at this exploratory endpoint at the 58 patients who were valuable at triple-negative breast cancer, and then that group of patients, also saw an improvement in PFS of 5.6 months, an improvement in overall survival of 9.9 months, very small group, but amazing data. The forest plots are exactly what you want to see, all the dots line up to the left of 1, and overall responses improved. One of the concerns with this drug has been toxicity. The toxicity showed no new toxicity signals, which is really important. Nausea is the biggest issue that we deal with. It's mostly grade 1 and 2, but still something that's important to manage. A little bit of hair loss, not much in the way of bone marrow suppression, which is interesting. Interstitial lung disease (ILD) or pneumonitis continues to be an important issue to follow. 12% of patients had ILD of any grade. Most of it was grade 1 and 2, but 3 patients died, representing 0.8%. So, this really highlights the importance of monitoring and managing pneumonitis. Regardless of that, few patients had a reduced ejection fraction, but again, very, in general, low grade. This is really a new standard of care, and the standing ovation was really due to the fact that all we do is dedicate ourselves to trying to help patients live longer and better with their cancers, and in this trial, we have a huge win that has no qualifications. We can help patients not only control their disease longer but live longer with T-Dxd compared to standard chemotherapy. Dr. Allison Zibelli: So, Hope, I know as a practicing medical oncologist, I find that our metastatic triple-negative patients are often the biggest therapeutic challenges for us. Will they be doing larger studies with these patients that are HER2-low? Dr. Hope Rugo: It's a really good point. About 65% of patients with hormone receptor-positive disease or so-called HER2-low, centrally confirmed in the study. So, a fair number of people, about a quarter, did not have HER2-low disease when they were tested centrally. In the triple-negative population, who really are ER, PR, HER2- by standard definitions, about a third of the patients might have HER2-low disease. So, there's a lot of interest in further exploring that and looking at the patients who have ultra-HER2-low disease, so between and 1 plus a little bit of expression. That's been studied in the hormone receptor-positive population in DESTINY-Breast06. But there's a lot of interesting further defining that triple-negative population, so to speak, they're going to be triple-negative plus now and understanding what the benefit is in that population. So definitely will be looked at more now moving forward. Dr. Allison Zibelli: Thank you. So, let's move on to Abstract 1002. And the results from the phase 1, 2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate, and patients with HER3 expressing metastatic breast cancer. What are your thoughts about this study? Dr. Hope Rugo: That's a really interesting, another one of these second- to third-generation antibody-drug conjugates. It's just the antibody, instead of being the usual, sort of, HER2 or TROP2 that we're used to thinking about is directed to HER3, 1 of the HER family of proteins. This is interesting. There's actually been a lot of work trying to target HER3 with naked antibodies with disappointing results, although I have to say most of the studies really didn't push it too far. So, with this antibody drug construct, deruxtecan, which is the same as in T-DXd and another TROP2 ADC Dato-DXd is used. So, I will say they do need to change the toxin in the next generation of ADCs. But they looked at, at first did a dose-finding study which has previously been presented, and then a dose expansion in both hormone receptor-positive HER2-negative disease and triple-negative disease. All the triple-negative patients had HER3 high disease by immunohistochemistry, and the hormone-receptor-positive patients were enrolled in 2 cohorts, HER3 high and HER3 low. And the median number of prior treatment regimens that patients had received in the hormone-receptor-positive group was 6 and 2 for the triple-negative group, but there was a huge range, up to 13 lines of treatment. They only had 14 patients with HER2+ disease. So, it's a little bit hard to know what to do with that patient group, but they were heavily pretreated 5.5 prior lines of therapy. The confirmed overall response rate in the 113 patients with combined HER3 high and low was 30%, very impressive, heavily pretreated patients. For triple-negative disease all HER3 high, it was 23%. Again, very nice. And there were 14 patients with HER2+ disease that also were HER3 high. It was about 43%. So those are nice responses, but we always want to know how durable is that. The duration of response ranged from 6 to over 8 months in those 3 different groups. So, these were quite durable. It wasn't any 2- to 3-month duration of response. So very impressive. And then when they looked to see, did it matter whether you had HER3 expression that was high or low in the hormone-receptor positive group, they actually did see responses in the HER3-low group, some very good responses. Overall, there were less patients in that group, but it does suggest that maybe you would still see responses in the HER3-low group, very impressive. And then 1 really interesting correlative study they did was they looked to see what happened to the HER3 expression on the tumor cell over time, and it went down. So, you treated the HER3 expression in most of the patients just dropped off completely, which is really interesting. It didn't have any association with clinical activity, but it's sort of an interesting correlative endpoint. This is a drug that overall was pretty well tolerated. They saw a similar toxicity to T-DXd with a lot of nauseous, a little bit of alopecia, a little bit more bone marrow suppression than we're used to seeing with T-DXd. So, neutropenia was seen in about 10% of patients at the lower dose and about a quarter of the patients at the higher dose. Overall, pretty well tolerated. Now, interstitial lung disease is a toxicity with this construct, and they saw ILD of 7% but most cases were grade 1 and 2. The other interesting toxicity that's unique to this agent is thrombocytopenia. So, they saw a grade 3 or greater rate of thrombocytopenia of 27% in the lower dose group, and in the larger group that received the higher dose, 39% of grade 3 or greater thrombocytopenia, so platelets less than 100,000. Turns out that when you stop the drug, the platelets do come back, so that's a good thing. Sometimes we saw long-term thrombocytopenia with T-DM1. They didn't see bad toxicity like bleeding, but it is something that needs to be managed with this drug because we're not great at managing thrombocytopenia. In any case, it has fast-track designation for another solid tumor, not breast cancer, and we'll have to see where this fits into our dizzying array of very effective ADCs now. Dr. Allison Zibelli: The practicing medical oncologist is not used to testing for HER3 in our patients with breast cancer. How common is it? Dr. Hope Rugo: HER3 expression is quite common in hormone receptor-positive disease, a little less common in triple-negative breast cancer. So, I think that we would see expression if we were going to be treating patients with this particular approach. Dr. Allison Zibelli: All right. Let's move on to Abstract 507, which reported long-term outcomes of adjuvant denosumab in breast cancer, specifically fracture reduction and survival results from 3,425 patients in a randomized double-blind, placebo-controlled ABCSG-18 trial. What are your thoughts about this study? Dr. Hope Rugo: Well, this trial, this is an update of a study that previously has been presented and published, most recent publication was in Lancet Oncology in 2019, and these patients were randomly assigned to receive denosumab at 60 milligrams, important to note the dose, subcutaneously every 6 months versus placebo every 6 months, and they did get placebo subcutaneous injections. And this treatment continued through their endocrine therapy. They showed a dramatic reduction in fracture rate, and that has been maintained over time. We were really surprised enough to suggest that maybe Austrian people didn't go into the sun, so they got more Vitamin D deficiency, hard to know, but the hazard ratio is 0.5. It's unbelievable the number of fractures, 92 for denosumab but 176 for placebo, a P value of less than .0001. So, this is a real endpoint, treating patients who are receiving endocrine therapy that, in this case, non-steroidal aromatase inhibitor therapy that can increase bone loss, have a reduced fracture rate when they received denosumab. So that is the big take-home message, and a medium follow-up of 8 years. But the secondary endpoints included disease-free survival. They had about 20% disease-free survival events and 8% deaths, and what they saw was really interesting. So, the caveat is that 16% of patients were unblinded at the first analysis and half of them got denosumab, so it messed up their results a little bit, but the disease-free survival was significantly better in patients who received denosumab, and the hazard ratio of 0.83 and the hazard ratio does not cross 1. So that's very interesting, and even overall survival, they looked at 2 other endpoints, bone metastasis-free survival, and overall survival. They also trend towards an improvement with a hazard ratio of 0.8 for both of them. And they didn't actually see toxicity. So, patients' brittle bone fractures and osteonecrosis of the jaw (ONJ) are all concerning, but they really just did not see any risks in this patient population. I think there was 1 patient that had what they thought was a brittle bone fracture. Obviously, they watched the mouth very carefully as well. Really dramatic, and I think it's kind of disappointing that we never had any registration approach in this, and also not well-understood why the D-CARE study did not show a benefit, but I think D-CARE was designed differently. This is a better design to focus on our patients and the specific issues, and I think it's intriguing and should be considered as part of our treatment regimen for patients who are at risk for bone loss and have early-stage breast cancer on an aromatase inhibitor. Dr. Allison Zibelli: I've been using DEXA scans and offering denosumab to my patients on AIs that have osteopenia or osteoporosis. Should we be considering it in women with normal bone mass? Dr. Hope Rugo: I think not yet. Unfortunately, this trial was not immediately powered for cancer outcome, although the data are very encouraging. We don't know what the relationship is to bone loss, and providing an environment that's friendlier for cancer cells. So, do you have to have bone loss in order to have the risk that you're reducing with these agents? Certainly, that's what we've seen with zoledronate. So, I think that we don't have sufficient data to use this simply to treat cancer, but I do think that we should be considering this as an agent to give patients who have bone loss, either when you're starting an aromatase inhibitor or during the course of therapy. I think it's well tolerated, and a subcutaneous injection is not difficult. One of the questions that's come up for people is do you get bone loss that increases your risk of fracture after you stop therapy. But clearly from these updated data, these patients were off therapy. They did not have an increase of fractures and the patients treated with denosumab fared much better, I mean the hazard ratio of 0.5. Dr. Allison Zibelli: Let's move on to TROPiCS-02. That's LBA1001. This is a randomized phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with hormone receptor-positive, HER2-negative advanced breast cancer. How do you think this study will impact practice? Dr. Hope Rugo: That's a great question. I presented this data, and I think I presented it on a Saturday, and on Sunday we saw the plenary talk of DESTINY-Breast04. These patients enrolled in TROPiCs-02 had a median number of lines of prior chemo 3 with a range of up to 8 actually, compared to a median number of lines as 1 in the DESTINY-Breast04 population. We included all hormone receptor-positive HER2 negative-advanced breast cancer, not centrally confirmed. They included just the HER2 low subset that was centrally confirmed. Everybody in our study had received prior CDK4/6 inhibitors compared to about 70% in DB04. And then 95% of patients in this trial had visceral mets. So, we did really treat a patient population who had very advanced high risk hormone receptor-positive breast cancer. As you know, we saw an improvement and progression-free survival with a hazard ratio of 0.66 meeting the endpoint. We needed a hazard ratio of 0.7, highly statistically significant P value .0003, but the median difference in PFS was only 1.5 months, and overall survival data is not yet mature. So that's brought up the question about how this drug should be used because there was a big fall off in the first 2 months where patients had rapid disease progression with heavily pretreated chemotherapy-resistant disease. We did landmark analyses and there were big separations in PFS at 6, 9, and 12 months, and 12 months, it was 21% patients free of progression and death at 1 year versus 7% for the TPC arm. So, it was a tripling of patients who were free of progression at one year. I think that's clinically relevant. This drug is associated with more neutropenia. That's the primary issue to manage, and probably half of the patients need growth factors at some point. When we looked at other endpoints response to ratio response, etc., we're better with Sacituzumab. So where does this all fit into our treatment paradigm. I think there's the HER2-low patients who will now receive T-DXd up in the, I hope, second line and not in lieu of endocrine therapy, when they're ready for chemo. But there are patients who don't have HER2-low disease and then there are patients who are going to be in the later line setting. So, I do think it still has a place in the treatment department, receptor-positive metastatic breast cancer. The results show that it was better than chemotherapy, physician choice based on our national and international guidelines, and that's better for our patients to have that option. Overall survival data obviously is looked for with great interest and that will help us put this into the right paradigm. And then I also hope that real world data will help us understand how sequential treatment with these different ADCs will benefit our patients. Dr. Allison Zibelli: This is really exciting. Do you think that we're maybe coming toward the end of conventional chemotherapy, especially for women with HER2-positive disease? Dr. Hope Rugo: I wonder if we are. I think we were interested in T-DM1 for HER2-positive disease early on. We've seen some really nice pathologic complete response data as well as adjuvant data in the attempt trial in patients who had stage I disease. Now that we have these second-, third-generation ADCs, T-DXd, I think this could potentially completely replace our chemotherapy. We still have to deal with alopecia. And I will point out ADCs are still chemotherapy. They're just a much more efficient and effective way of delivering treatment, and we need to be very careful to manage the toxicity. Dr. Allison Zibelli: Next, we're going to talk about the main pain trial that's LBA1004, which is a randomized phase 2 trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or hormone receptor-positive HER2-negative metastatic breast cancer, in other words CDK4/6 after CDK4/6. What are your takeaways here? Dr. Hope Rugo: First, just amazing that an investigator-initiated trial could do this well and be placebo-controlled. So, kudos to the principal investigator (PI) [Dr.] Kevin Kalinsky. This trial is a small phase 2 trial. A reasonable number, 119 patients were randomly assigned and evaluable patients could have received up to 1 line of prior chemotherapy for metastatic disease. If you had received prior exemestane, you received fulvestrant, if you received prior fulvestrant, you received exemestane, and actually if you looked at the number of patients who had received fulvestrant, it was 99 versus only 20 with exemestane. So important to keep in mind. If you looked at the overall population where the primary endpoint was progression-free survival, the hazard ratio is 0.57, just median PFS of 2.8 months in patients receiving endocrine therapy and placebo and 5.3 months for patients receiving endocrine therapy and ribociclib. So was this ribociclib after ribociclib or ribociclib after something else. 86% of patients had received palbociclib as their prior CDK4/6 inhibitor, and only about 10% to 14% had received prior ribociclib. So, there's a predominance of palbociclib followed by ribociclib. The other thing that's important to keep in mind is how sick this patient population was. Very few had received prior chemotherapy in the less than 10% range, visceral metastases in about 60%. So that's helpful. Only 19% or so had received 2 or more endocrine therapies from metastases. So, most people did this as their second line treatment. The PFS, when you looked at fulvestrant or exemestane, looked like the benefit was relatively similar, but you know you got 20 patients in the exemestane arm. The hazard ratios, looking at the subgroup analyses, all looked pretty similar, and the overall response and clinical benefit rate were better with continuing the cyclin dependent kinases (CDK) inhibitor. There was interesting sub-analysis looking at mutations and how that affected things. And they looked at patients who had ESR1 mutations or had wild-type ESR1. 42% had ESR1 mutations at study entry, very similar to what we've seen. In that group of patients, remember it's only 33 where they had this analysis, they saw a lot of other mutations. So p53, PIK3CA, FGFR, CCND1—those patients did not benefit. Only 33 patients. No benefit at all, very short PFS, about 3 months. The patients who had ESR1 wild type seemed to benefit a lot, 45 patients going from about 3 months to a little over 8 months. So, this is all hypothesis-generating data. I wouldn't run out and use this as your standard of care now because it is small data. But when the patient doesn't have other good options, I certainly would consider switching the CDK and going on, add that to the next line endocrine therapy. It's important to switch the endocrine therapy. I think we really need to look at the ongoing phase 3 trials to give us better evidence basis and understand the impact of mutations and prior therapy on who might benefit from continued CDK inhibitors after progression on a CDK inhibitor. Dr. Allison Zibelli: I think this is a really exciting trial. We all have a lot of patients on palbociclib and letrozole who've been on for 4, 5 years, and would like to continue with this kind of treatment because the side effects are really manageable. So, I look forward to seeing what's coming in the future with the phase 3 trials. So, let's talk about Abstract 1015, which I thought is a great idea. It looks at the quality of life with ribociclib plus aromatase inhibitor versus abemaciclib plus AI as first-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer, assessed via matching adjusted indirect comparison. Could you tell us what matching adjusted indirect comparison is and why you chose this for the study? Dr. Hope Rugo: It's an interesting question. How do you compare across trials? So, matching this kind of make analysis, we'll call it a make analysis for the purposes of this discussion, allows you to match patients and weight based on their characteristics that might affect patient reported outcomes. And that actually is a way of trying to do a fair cross-trial comparison. So basically, take the study population, you match the inclusion and exclusion criteria, and then you weigh the different criteria so that you can try and make a better association. It's the best way we know of comparing across trials. You know, a lot of people ask why we didn't have PALOMA-2 in here, and that's because they used a different patient reported outcome tool. So, you have to use the same patient reported outcome tool in order to compare. So that's why we did this analysis, and it sort of came on the heels of a survey that Fatima Cardoso presented at San Antonio in 2021, where patients identified diarrhea as a symptom they really didn't like more than everything else. And you can imagine, I think we all have that experience in practice, the unexpected nature of diarrhea and the fact that it does limit your activities and, therefore, quality of life are important. In this analysis, interestingly but not surprisingly, ribociclib favored abemaciclib in diarrhea, and there can be associated appetite loss, so ribociclib also favored abemaciclib for appetite loss. And I thought the last one was interesting—fatigue—because I wouldn't have assumed that fatigue would be different. And maybe it's associated with diarrhea. They have these funny arm symptoms that were better. We don't really know why that was, and it's hard to assess again. We're really not clear based on the differences between the drugs. So, there are limitations to the analysis, but I think that it helps us really in individual patients try and match patients' underlying symptoms with the best treatment to offer them the best quality of life as they're being treated in the metastatic setting. Dr. Allison Zibelli: I thought this study was great because it really centered the experience of the patient and the wishes of the patient. You don't see that designed into many clinical trials, the way this was. So, I thought that was a great feature of this study. Dr. Hope Rugo: I will say that all of the 3 studies that looked at CDK inhibitors, all those 3 studies included patient-reported outcomes. That's an important new approach that is really being focused on. Dr. Allison Zibelli: Do you consider the CDK4/6 inhibitors equivalent in efficacy, and could you substitute them to try to get the side effect profile that you want? Dr. Hope Rugo: Well, I think that we saw in the early stage setting that there are differences. Now, across the different trials, there are big differences in patient populations and inclusions as we saw in the PALOMA-2 results that were presented at ASCO [Annual Meeting], whether the patients had prior chemotherapy like in PALOMA-3, whether they had a short disease-free interval, the higher risk patients in PALOMA-2. The PALOMA trials were more broadly inclusive than the other 2 studies, the MONALEESA and MONARCH series of trials. So, we do have to be a little bit careful about comparing apples to oranges, but we have the early-stage results of MONARCH E showing a clinically important difference in outcome whereas the PALLAS and Penelope-B trials didn't. So that sort of puts us into a little bit of a question period. Are these all patient populations or are there differences between the agents? The PFS and the metastatic setting, all the hazard ratios line up. So, in truth, although I know the activity against cyclin-independent kinases are different between agents, we don't still really understand the clinical differences in efficacy, but I think we all are practicing using evidence-based medicine. I wouldn't, for example, substitute a different CDK4/6 inhibitor for abemaciclib in the treatment of early-stage breast cancer. We have to just learn how to manage the diarrhea and use prophylaxis and dose reduce early to manage this and make it tolerable for our patients. And in the metastatic setting, I think we need to follow evidence-based guidelines and use the best data available to decide on the right treatment approach and sequencing for our patients. Dr. Allison Zibelli: Thank you, Hope, for coming on the podcast today. This was a really interesting review of one of the most exciting ASCO [Annual Meetings] I've been to. And thanks for sharing your valuable insights with us and helping us make sense of all this really new exciting data. We really appreciate it. Dr. Hope Rugo: Thank you. And thank you so much for inviting me. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You will find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. That really helps other listeners find us. Thank you.   Disclosures: Dr. Allison Zibelli: None disclosed. Dr. Hope Rugo: Honoraria: Puma Biotechnology, Mylan, Samsung Bioepis, Chugai Pharma, Blueprint Medicines Consulting or Advisory Role: Napo Pharmaceuticals Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Genentech, Merck, Odonate Therapeutics, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Ayala Pharmaceuticals, Astellas Pharma, Seattle Genetics, Macrogenics, Boehringer Ingelheim, Polyphor Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Chris Grainger explains Explorer, Nx's recent addition. It's a “Data Frame” library which sounds far more nebulous than it is. It lets us explore and manipulate two-dimensional data like we already do with DB tables, spreadsheets, CSV files, etc. Only this works in memory, is faster, and has predefined functions that make it very powerful. Explorer fills an important slot in the overall pie for data science and ML in Elixir. However, Explorer is also one of the tools that “regular” Elixir devs can take advantage of today! Show Notes online - http://podcast.thinkingelixir.com/104 (http://podcast.thinkingelixir.com/104) Elixir Community News - https://twitter.com/josevalim/status/1535008937640181760 (https://twitter.com/josevalim/status/1535008937640181760) – At ElixirConf EU, José Valim announced there is an ongoing PhD scholarship for researching and developing a type system for Elixir that is powered by set-theoretic types. - https://www.irif.fr/~gc/ (https://www.irif.fr/~gc/) – Giuseppe Castagna's Home Page. Senior Research Scientist - https://arxiv.org/abs/2111.03354 (https://arxiv.org/abs/2111.03354) – Programming with union, intersection, and negation types - https://twitter.com/fhunleth/status/1534826558774464512 (https://twitter.com/fhunleth/status/1534826558774464512) - https://podcast.thinkingelixir.com/72 (https://podcast.thinkingelixir.com/72) – Typecheck interview - https://github.com/ergo-services/ergo (https://github.com/ergo-services/ergo) – We learned of a Golang library called “ergo” that is an “actor based Framework for creating microservices using technologies and design patterns of Erlang/OTP in Golang” - https://twitter.com/erlangforums/status/1534822378722713601 (https://twitter.com/erlangforums/status/1534822378722713601) – Patch Package OTP 25.0.1 Released - https://erlangforums.com/t/patch-package-otp-25-0-1-released/1526 (https://erlangforums.com/t/patch-package-otp-25-0-1-released/1526) – Minor bug fixes. Zlib updated - https://flowbite.com/docs/getting-started/introduction/ (https://flowbite.com/docs/getting-started/introduction/) – More free alternative to TailwindUI - https://github.com/tailwindlabs/tailwindcss/releases/tag/v3.1.2 (https://github.com/tailwindlabs/tailwindcss/releases/tag/v3.1.2) – tailwindcss CLI v3.1.2 released which includes postcss-import into the CLI bundle - https://twitter.com/adamwathan/status/1535989815778463746 (https://twitter.com/adamwathan/status/1535989815778463746) – Adam Wathan, the Tailwind CSS guy, had a fun quote that we liked. - “Open source is “right to repair” for software — nothing more, nothing less. Maintain that attitude and any frustration or entitlement you feel will be replaced with gratitude. Better for maintainers, and better for you.” Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Discussion Resources - https://github.com/elixir-nx/explorer (https://github.com/elixir-nx/explorer) - https://hexdocs.pm/explorer/Explorer.html (https://hexdocs.pm/explorer/Explorer.html) - https://hexdocs.pm/explorer/Explorer.DataFrame.html (https://hexdocs.pm/explorer/Explorer.DataFrame.html) - https://hexdocs.pm/explorer/Explorer.Series.html (https://hexdocs.pm/explorer/Explorer.Series.html) - https://twitter.com/cigrainger/status/1518896955921154048 (https://twitter.com/cigrainger/status/1518896955921154048) – Tweet about using Rustler and Rustler Precompiled - https://hexdocs.pm/explorer/exploring_explorer.html (https://hexdocs.pm/explorer/exploring_explorer.html) – Includes a “Ten Minutes to Explorer” Livebook guide in the docs to walk you through setup to getting started with a good overview. - https://www.cigrainger.com/posts/introducing-explorer/ (https://www.cigrainger.com/posts/introducing-explorer/) - https://databricks.com/glossary/what-are-dataframes (https://databricks.com/glossary/what-are-dataframes) - https://pandas.pydata.org/docs/user_guide/dsintro.html (https://pandas.pydata.org/docs/user_guide/dsintro.html) - https://dataframes.juliadata.org/stable/ (https://dataframes.juliadata.org/stable/) - https://cran.r-project.org/web/packages/tidyr/vignettes/tidy-data.html (https://cran.r-project.org/web/packages/tidyr/vignettes/tidy-data.html) - https://github.com/dashbitco/table (https://github.com/dashbitco/table) - https://huggingface.co/ (https://huggingface.co/) - https://www.amplified.ai/ (https://www.amplified.ai/) – Chris' company - https://pandas.pydata.org/ (https://pandas.pydata.org/) - https://en.wikipedia.org/wiki/Extract%2Ctransform%2Cload (https://en.wikipedia.org/wiki/Extract%2C_transform%2C_load) - https://github.com/tyrchen/ex_polars (https://github.com/tyrchen/ex_polars) – Library that got him started with Rust, Rustler and working with polars - https://hexdocs.pm/rustler_precompiled/RustlerPrecompiled.html (https://hexdocs.pm/rustler_precompiled/RustlerPrecompiled.html) - https://github.com/philss/rustler_precompiled (https://github.com/philss/rustler_precompiled) - https://huggingface.co/docs/transformers/main_classes/tokenizer (https://huggingface.co/docs/transformers/main_classes/tokenizer) - https://github.com/elixir-nx/tokenizers (https://github.com/elixir-nx/tokenizers) - https://docs.rs/crate/polars/0.22.0 (https://docs.rs/crate/polars/0.22.0) - https://github.com/pola-rs/polars (https://github.com/pola-rs/polars) - https://parquet.apache.org/ (https://parquet.apache.org/) - https://avro.apache.org/ (https://avro.apache.org/) - https://arrow.apache.org/overview/ (https://arrow.apache.org/overview/) - https://vega.github.io/vega-lite/ (https://vega.github.io/vega-lite/) - https://www.rdocumentation.org/packages/dplyr/ (https://www.rdocumentation.org/packages/dplyr/) Guest Information - https://twitter.com/cigrainger (https://twitter.com/cigrainger) – on Twitter - https://github.com/cigrainger/ (https://github.com/cigrainger/) – on Github - https://cigrainger.com (https://cigrainger.com) – Blog Find us online - Message the show - @ThinkingElixir (https://twitter.com/ThinkingElixir) - Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) - Mark Ericksen - @brainlid (https://twitter.com/brainlid) - David Bernheisel - @bernheisel (https://twitter.com/bernheisel) - Cade Ward - @cadebward (https://twitter.com/cadebward)

“We should totally hang out sometime!” never actually hangs out  The epitome of adult friendships. Have you ever said that to someone even though you know you have no intention of actually making time for it in the near future? TBH, I'm guilty of it too…  Jeanette Tapley is bringing the  HEAT on the podcast today talking all about navigating adult friendships. When I tell you this episode was basically scripted for anyone who is finding it difficult to be in the community as a young adult — NO. JOKE. TUNE IN for some company and conversation while you're making dinner, going on a walk, or driving down the road. 

In this episode, my guest discusses sales coaching and its importance in training. Within one month of training, 87% of skills are lost. Coaching allows sales leaders and managers to change what they do and how they do it and better transfer positive behaviours to their teams.   You'll learn a lot about the alchemy of communication and personal development from my guest, who has a background in selling to large corporations. My next guest is an NLP life coach, professional hypnotherapist, EFT practitioner, and the founder of Aurate Limited. She says sellers must focus on nurturing salespeople and coaching effectively for sales success.   Welcome to Scale Your Sales Podcast Jacqueline Norton   Timestamps:   00:00:00 - Maintain the Alchemy of Communication and Personal Development   00:06:50 - 4 Ways of Knowing   00:09:55 - Ancient Medicine Wheel / Different Levels of Consciousness and Developing Awareness   00:12:06 - Why Empathy is Important in Sales   00:17:30 - Diversity in Sales and The Importance of Inclusivity in Sales   00:22:05 - How to Coach your Sales Team   Jacqueline Norton LinkedIn: linkedin.com/in/jacquelinenorton   Websites: discovery.aurate.co.uk/discovery/ (Company Website)   Twitter: AuArtistsaa1   Janice B Gordon, the awarding-winning Customer Growth Expert and founder of Scale Your Sales Framework. She is by LinkedIn Sales 15 Innovating Sales Influencers to Follow 2021, the Top 50 Global Thought Leaders and Influencers on Customer Experience Nov 2020 and 150 Women B2B Thought Leaders You Should Follow in 2021 Janice helps companies worldwide to reimagine revenue growth through customer experience and sales.   Book Janice to speak virtually at your next event https://janicebgordon.com   LinkedIn: https://www.linkedin.com/in/janice-b-...   Twitter: https://twitter.com/JaniceBGordon   Scale Your Sales Podcast: http://scaleyoursales-podcast.co.uk/   More on the blog https://scaleyoursales.co.uk/blog   Instagram: https://www.instagram.com/janicebgordon   Facebook: https://www.facebook.com/ScaleYourSal...

Today Alex & Richarrd discuss Rolling Stone's 200 greatest hip hop albums and their love languages, they also answer a question from a viewer whose ex-boyfriend and best friend are hanging out. Make sure to subscribe to the channel and drop a like for more episodes!00:00 Intro00:32 Maintain Update02:36 Story of “We Don't Belong Together”04:09 Justin Bieber 07:46 200 Greatest Hip Hop Albums12:55 Who would have the best hip-hop collab tape?15:46 Kodak & Drake album on the way?17:40 Woo & Richarrd's love languages21:33 “My ex-boyfriend and my best friend are hanging out what should I do?”28:24 Is it okay to talk to your friend's ex if they're a 10?30:12 Is J Cole the best basketball player ever?33:21 Woo is Bruce Brown in pickup games34:49 Is Woo the DPOY in pickup games?ASK US QUESTIONS FOR OUR NEXT EPISODE: https://www.surveymonkey.com/r/96H5H59https://www.surveymonkey.com/r/96H5H59FOLLOW US ON INSTAGRAM:https://www.instagram.com/thatstarwoohttps://www.instagram.com/charrd__https://www.instagram.com/maintainnetworkYOUTUBE CHANNEL: https://youtube.com/channel/UCNaVTyhp-5lDe3kQngkmbYAFOLLOW US ON TIK TOK: https://www.tiktok.com/@maintainnetwork?is_from_webapp=1&sender_device=pcCLIPS CHANNEL: https://www.youtube.com/channel/UCo33UHuDMszKbhHK1REilAQ

Josh Neighbors joins Alex Frank on the Locked on Bearcats Podcast. The guys share their thoughts on the potential for Cincinnati Athletics to maintain their momentum as they head into their final year of AAC play and look towards the Big 12. The guys discuss the future of the Cincinnati Football under Luke Fickell & Cincy Basketball under Wes Miller. Can Cincinnati Maintain Momentum As They Head Into The Big 12? https://www.youtube.com/channel/UCIaiqufEekxiTnnLc129t2g WANT MORE DAILY BIG 12 FOOTBALL AND BASKETBALL CONTENT? Follow & Subscribe to the Podcast on these platforms…

In managing the trajectory of your career, one of the most important assets you have is your reputation. What other people think of you as a) a colleague, leader, or team member, and b) your behavior around others, including clients and stakeholders, will impact their ability to consider you for promotions internally, as well as job opportunities in other organizations. I am sure you have heard the saying ‘your reputation precedes you.' That was true before social media and the internet, and it's even more acute now since there are so many ways we can learn about each other online. I encourage you to take an active role in protecting and managing your reputation. And in this podcast episode, I discuss a few ideas that I believe you can use to help you showcase your competence, likeability, and credibility as a professional. Podcast Episode Timestamps: 04:10 - About reputation 06:41 - Reputation and your network 12:44 - Reputation and social proof 16:14 - Your reputation will enhance or decrease your gravitas 17:12 - People's opinion of you and your online presence 19:58 - How you manage success and failure affects your reputation Links mentioned in this episode: Episode 81: A career coach's top tip for job interview preparation to guarantee your best performance. Episode 82. How to show executive presence in a job interview Episode 83: 6 Unexpected ways on how to nail your next job interview LinkedIn Audit service Other ways to enjoy this podcast: Read the full blog on the podcast website Download a transcript of this episode. Are you new to The Job Hunting Podcast? If so, here is a bit about your host: Hello, I'm Renata Bernarde, the Host of The Job Hunting Podcast. I'm also an executive coach, job hunting expert, and career strategist. I teach corporate, non-profit, and public professionals the steps and frameworks to help them find great jobs, change, and advance their careers with confidence and less stress.  If you are 1) an ambitious professional who is keen to develop a robust career plan, 2) looking to find your next job or promotion, or 3) you want to keep a finger on the pulse of the job market so that when you are ready, and an opportunity arises, you can hit the ground running – then this podcast is for you. In addition to The Job Hunting Podcast, I have developed a range of courses and services for professionals in career or job transition. And, of course, I also coach private clients.  So there is no excuse – I'm determined to help you! I want you to feel empowered, nail your next job, and have the career you want. Subscribe to the newsletter. A free resource for job hunters: The Optimized Job Search Schedule. Learn more: www.renatabernarde.com. Book a time to discuss 1-1 coaching and achieve your goals faster Or please email me at rb@renatabernarde.com.       Please support The Job Hunting Podcast: Follow, subscribe, share, rate, and review: Thank you so much again for listening to the episode. Please leave us a review and give it a 5-star rating on Apple Podcast if you enjoyed the content. An appraisal is the best gift you can give to a podcaster; I'll be so happy you wouldn't believe it! Writing a review and giving it five stars helps the podcast reach more people like you who want guidance and support in job hunting and career advancement. Enjoy the episode, and ciao for now! RB Renata Bernarde | Job Hunting Expert | Founder, Pantala Academy Book a time to discuss 1-1 coaching and achieve your goals faster rb@renatabernarde.com      www.renatabernarde.com   --------- Host: Renata Bernarde Editing: Camille Cariño Music: Scott Holmes Contact us: rb@renatabernarde.com The Job Hunting Podcast is a podcast by Pantala Pty Ltd. Pantala acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Bunurong people. We pay our respects to their Elder's past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures.

It is estimated that 15 to 20 million Americans struggle with osteoporosis and 80% of those are women. 1 in 2 women by the age of 50 will break a bone because of osteoporosis. With that staggering statistic, what can we do right now to maintain strong and healthy bones? What food should we eat, whether we are 70 years old or 50 or 30 or 20 or even a teen, to start changing those numbers for the better? We need strong but flexible bones - not hard and brittle bones. In today's show, we'll discuss what substances rob our bones of nutrients and what foods to incorporate to create those strong, flexible bones.

Faster Masters Rowing Radio - the podcast for masters rowers. Tips, advice and discussion from Marlene Royle and Rebecca Caroe. Support this show with a donation https://fastermastersrowing.com/podcast Timestamps 01:00 This Past Week - what we do to advocate for masters rowing - who is the fund raising group in your club? 04:00 Corporate rowing if you're interested in a discussion - get in touch. 05:00 Marlene's rigging dock talk 07:00 book of the Month with Jess di Carlo is Olaf Tufte's Skjerpins. https://www.ark.no/boker/Olaf-Tufte-Skjerpings-9788241953811 This literally means “sharpening” or more prosaically “Get a grip - you can always get better”. It's in Norwegian and Jess used Kindle translate function to read it. 10:30 Olaf is strong on visualisation and spent 10 minutes working on the first stroke before the Beijing Olympic final. 15:00 Hiking with his family - he found himself in trouble and said 'get the breathing right and the head will follow'. 21:00 Start rowing slowly and rebuild the stroke from the basics after a set back. 22:30 Rest and recovery Peaks require a rest and reset before another peak event. Recover - between your sessions each week - between each is a recovery period. Sleep is terrific for recovery as is nutrition and hydration. Glycogen in your muscles fuels muscle action - heavy legs 26:30 Doing 2 sessions a day versus 2 days between sessions. Hard and easy days take planning. 28:30 Rest and sleep means 7-9 hours per day asleep. When you sleep your hormones are active. Maintain weight, mental sharpness and dehydration. Interrupted sleep is a common issue for masters. Naps are a useful tool to use. 30:30 Other types of rest include sports massage, sauna, contrast showers (hot and cold) all help flush your system, Plan the rest days in a week's schedule Plan the rest weeks in an annual schedule. Cross training can be a rest and a change too, 33:00 Heart Rate Variability measures the fluctuation of what is happening between your heart beats. Compares the sympathetic and parasympathetic nervous systems. Different ways to track are available. Get age group comparison data and personal day to day changes in your analytics. High values mean you are more recovered. 35:00 Active Recovery is rest or sleeping an extra hour. Simple ways to test your recovery. Check your waking heart beat in the morning for 1 minute. If it's 10 beats higher than normal don't do hard work that day or take a rest day. 37:00 Rebecca used to track using the Daily Diary from Harry Mahon https://www.rowperfect.co.uk/how-useful-is-a-training-diary-for-rowing/ If it's 5 beats higher than normal you could have a virus coming on. Err on the side of caution. 40:45 De-conditioning takes a long time. You have to stop training for a long time to get to lose your fitness. Two sessions a week are enough for fitness maintenance. Keep it low intensity. Two sessions a week are enough for maintenance at low intensity

Maintain

This is a great example of why the Scars and Guitars podcast exists because Rogelio covers a heap of territory other shows will never explore. He discusses the group's new album, Maintain, which is the catalyst for the chat, but it's his comments on many of the social issues affecting the United States such as race and identity, the band's influence on Fred Durst and Limp Bizkit; and Rogelio's crucial role in bringing heavy metal to the rap and hip hop audience which make this conversation one of the finest conversations broadcast on the show.

In this week's FRIDAY FIELD NOTES, Ryan Michler breaks down 10 tactics you should employ to engage in respectful and worthwhile discussions.  Hit Ryan up on Instagram at @ryanmichler and share what's working in your life.   SHOW HIGHLIGHTS   Maintain a humble attitude Keep your biases in check Me mindful of how your emotions affect you Be just with offing views Stay on topic Be civil Help your discussion partner save face Do away with rhetorical attacks Demand that the other person civil as well Be understanding Dont fold Be willing to walk away   Want maximum health, wealth, relationships, and abundance in your life? Sign up for our free course, 30 Days to Battle Ready ⠀ Download the NEW Order of Man Twelve-Week Battle Planner App and maximize your week.

Always Learning To Maintain A Culture Of Excellence and Grow   Welcome to episode 129 of the Grow Your Law Firm podcast, hosted by Ken Hardison. In this episode Ken sits down with Mike Bottaro and they talk about how to maintain your culture of excellence and continue to grow. As a college student, Mike Bottaro knew he wanted to become a lawyer. There, Mike read a New England lawyer's book about standing up to large corporations on behalf of sick children.  Mike met that lawyer who inspired him to learn about personal injury law as a calling to help people and make our communities safer. Later in life, Mike suffered his own injuries and obstacles that grew his spiritual faith and gave empathy for the injured. It is these life experiences that Mike brings with him every day in helping his clients recover and achieve justice after a personal injury.   What you'll learn about in this episode: Always continuing to learn to maintain a culture of excellence Striving to differentiate yourself with authenticity Keeping core values front and center to strengthen a team Learning from those who have done it Fostering the bonds with team members Practicing law as an honorable endeavor   Resources:  Website: https://bottarolaw.com/ Mike Bottaro's Website: https://bottarolaw.com/about-us/meet-our-attorneys/mike-bottaro/ LinkedIn: https://www.linkedin.com/company/the-bottaro-law-firm-llc Facebook: https://www.facebook.com/RhodeIslandPersonalInjury Twitter: https://twitter.com/rilawyer   Additional Resources: PILMMA's Super Summit https://learn.pilmma.org/pilmma-super-summit-2021 The Mastermind Effect: https://www.pilmma.org/the-mastermind-effect/ PILMMA's Free Resources: https://www.pilmma.org/free-resources/ PILMMA Join Page: https://learn.pilmma.org/join-pilmma  

If you are interested in supporting us and want to pick up any of our books, products or coaching click this link: https://linktr.ee/abfitnesscenter About me: My name is Anthony Bevilacqua from AB Fitness Center and on this channel I show you how to hit your fitness goals by using Flexible dieting and myfitnesspal. I also teach you how to keep weight off by counting macros. Flexible dieting is the best way to help you on your weight loss journey. As a nutrition fitness professional we use the flexible diet to not only show you how to look good naked but also help you to build strength using powerbuilding. Building strength this way with help you to build a classic physique. As an Online coach these nutrition tips and nutrition guidelines will help you to keep weight off and add lean bulk. IIFYM can help you with strength training. I will show you how to stay motivated to lose weight with IIFYM weight loss. Subscribe here: https://www.youtube.com/abfitnesstrainer?sub_confirmation=1 Be Sure to follow me on INSTAGRAM  @abfitness Disclaimer: The information on this Channel and the resources available are for educational and informational purposes only.​ #myfitnesspal #weightlossjourney #nutritiontips

The Apostle Paul instructed the church in Corinth in 1 Cor. 11:1 to, "Imitate me, as I also imitate Christ." He was basically inviting them into his walk with God. There is a great need in this hour to instill a living legacy of knowing Jesus and His wonders into those within our spheres of influence. Join me this week on "Maintain the Flame" as I share (Pt. 4)  of this important theme on "Handing Down A Legacy" and prepare to be encouraged and stirred.

After multiple near-death experiences, Zeb Evans decided to build a business that was net positive on the world. However, he didn't realize that a custom internal productivity tool would become the business he was searching for. In 2017, Evans cofounded ClickUp, an all-in-one productivity management tool now valued at $4 billion.    Listen to Nathan and Zeb discuss:  Selling Disney DVDs from his hospital bed How a home invasion motivated him to drop out of school Starting his first company Fast Followerz from customized social tools How an unexpected seizure pushed him to move to Silicon Valley  Building ClickUp as an internal tool and discovering its value The early days of ClickUp and living in a stereotypical startup house Why investors were shocked that ClickUp was profitable  Maintain culture while scaling at a rapid rate  Why Zeb takes a bath every evening And much more tech startup advice…       Who do you want to see next on the podcast? Comment and let us know! And don't forget to leave us a 5-star review if you loved this episode.   Wait, there's more… If you enjoy the Foundr podcast, check out our free trainings. Get exclusive, actionable advice from some of the world's best entrepreneurs.    For more Foundr content, follow us on your favorite platform:  Foundr.com Instagram YouTube Facebook Twitter LinkedIn Magazine

Before you start your day, what is your routine like? How do you maintain focus and productivity all throughout? For today's episode, Raul talks about the number one asset that we all should have: Maintaining your focus. He also spills the secret behind maintaining focus by sharing his 10-step protocol to maintain peak focus throughout the day. Highlights What Raul's number one asset is What today's negative trend is when getting someone's attention The tools can help you communicate without meeting in real-time What stream of conscious thinking is The 10 step protocol to maintain peak focus throughout the day Episode Resources Connect with Raul Hernandez Ochoa https://www.linkedin.com/in/dogoodwork https://dogoodwork.io/work-with-raul https://dogoodwork.io/podcast 

The post 115: Maintain Unity appeared first on Nika Maples.

00:00:00 Intro 00:15:00 treethan predicts TSM last place this split 00:32:12 Zemelci asks Parth who he'd mind control at Riot to change LoL Esports 00:44:48 Bluejay's take: the LCS and FLY just lost one of the most valuable people in the scene 00:58:12 Franz asks Parth what made the 2016-17 TSM rosters so dominant. 01:20:35 Grubhub! 01:23:00 TwistedHitz wants to talk LCS viewership and lack of identity 01:26:45 Travis asks: can a team be popular without winning? 01:58:58 absolutelylovestickers predicts TL will be a clear favorite after Summer split, while 100T will fall below top 5 02:08:07 Outro